| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Gilman Steven C serves as a Director at AKBA and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 2 buys and 15 sells. Those positions are worth an estimated $455K at current prices.
Historically, Gilman Steven C's trades have earned a strong insider score of 70/100 across 10 rated trades. Over a 12-month horizon, 80.0% of those trades were profitable, with an average 12-month return of +22.1%.
The biggest single holding is VCEL (~$455K) as Director. The recent filings there lean toward selling, a net 70,900 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 21, 2020 | SCYX Scynexis Inc | Director | Buy | 4,000 | $6.25 | $25,000.00 | New | |
| Jun 8, 2020 | AKBA Akebia Therapeutics, Inc. | Director | Sell | 4,567 | $12.08 | $55,169.36 | -10.5% | |
| Nov 20, 2019 | AKBA Akebia Therapeutics, Inc. | Director | Buy | 5,800 | $3.43 | $19,894.00 | +24.2% | |
| May 1, 2019 | VCEL Vericel Corp | Director | Sale+OE | 7,500 | $16.81 | $126,094.50 | - | |
| Feb 28, 2019 | VCEL Vericel Corp | Director | Sale+OE | 7,500 | $18.02 | $135,129.00 | - | |
| Dec 3, 2018 | VCEL Vericel Corp | Director | Sale+OE | 8,500 | $17.75 | $150,908.15 | - | |
| Sep 4, 2018 | VCEL Vericel Corp | Director | Sale+OE | 9,000 | $12.03 | $108,270.00 | - |